U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C14H21NO2.ClH
Molecular Weight 271.783
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEPRYLCAINE HYDROCHLORIDE

SMILES

Cl.CCCNC(C)(C)COC(=O)C1=CC=CC=C1

InChI

InChIKey=LKHWKAGQNOMUFQ-UHFFFAOYSA-N
InChI=1S/C14H21NO2.ClH/c1-4-10-15-14(2,3)11-17-13(16)12-8-6-5-7-9-12;/h5-9,15H,4,10-11H2,1-3H3;1H

HIDE SMILES / InChI

Description

Meprylcaine (also known as Epirocaine and Oracaine) is a local anesthetic with stimulant properties that is structurally related to dimethocaine. Meprylcaine has a relatively potent inhibitory action on the monoamine transporter and inhibits the reuptake of dopamine, norepinephrine and serotonin. Oracaine is commonly used as the hydrochloride salt and is compatible with the known vasoconstrictors. It has a slightly more rapid onset than procaine with a slight increase in potency. The earliest symptoms of a toxic overdose are stimulation to the central nervous system, thus following the same symptoms as procaine. Not more than 400 mg. (20 ml. of a 2 per cent solution) should be used at any one time for the ambulatory patient. Oracaine, like metycaine, may be used for patients sensitive to the para-aminobenzoic acid derivatives. Oracaine hydrochloride is used at present mainly by the dental profession and in dermatologic surgery.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
7.6 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
2% solution of Oracaine for injections
Route of Administration: Parenteral
In Vitro Use Guide
Unknown